Single-Center Mid-term Experience with E-Liac Branched Device from Artivion®

Area of Science:

• Vascular Surgery
• Endovascular Techniques
• Aortic Aneurysm Repair

Background:

• Iliac branch device (IBD) use is increasing for less invasive endovascular repair.
• Clinical data on the Artivion® E-liac stent graft are limited.
• This study evaluates mid-term outcomes of the E-liac stent graft from a large single center.

Purpose of the Study:

• To assess the mid-term outcomes of the E-liac stent graft in patients with aorto-iliac aneurysms.
• To evaluate technical success, reintervention rates, and patency following IBD implantation.

Main Methods:

• Retrospective analysis of patients treated with E-liac stent grafts for aorto-iliac aneurysms (September 2015 - December 2022).
• Evaluation of postoperative outcomes including technical success, 30-day mortality, and reinterventions.
• Assessment of mid-term outcomes such as endoleak, hypogastric artery patency, and overall mortality.

Main Results:

• 82 E-liac stent grafts were implanted in 63 patients with a median follow-up of 38 months.
• Technical success rate was 95%, with no 30-day mortality.
• Internal iliac artery patency was 97.6% initially and 95.1% secondary patency; one IBD-related reintervention was performed.

Conclusions:

• The E-liac stent graft achieves high technical success rates.
• Good mid-term outcomes, including favorable patency and low reintervention rates, were observed.
• The E-liac stent graft is a feasible, safe, and effective option for treating aorto-iliac aneurysms.